Affordable Prescriptions for Patients Act

Bill 119 s 1041, also known as the "Biologics Patent Transparency Act," is a proposed piece of legislation that aims to make changes to title 35 of the United States Code in order to address issues related to the infringement of patents on biological products. The bill seeks to increase transparency and accountability in the patent system for biologics, which are complex drugs made from living organisms.

One of the key provisions of the bill is the requirement for the Secretary of Health and Human Services to establish a public database of patents related to biologics. This database would provide information on the patents held by manufacturers of biologics, as well as any patent disputes or litigation that may be ongoing. This increased transparency is intended to help prevent the infringement of patents on biologics and ensure that manufacturers are held accountable for their intellectual property rights.

Additionally, the bill includes provisions to streamline the patent dispute resolution process for biologics. This includes establishing a process for the timely resolution of patent disputes, as well as mechanisms for the sharing of information between patent holders and potential infringers. By making it easier for patent holders to enforce their rights and for potential infringers to understand their obligations, the bill aims to reduce the likelihood of patent infringement in the biologics industry. Overall, Bill 119 s 1041 is designed to protect the intellectual property rights of manufacturers of biologics and promote innovation in the development of these important medical products. By increasing transparency and accountability in the patent system for biologics, the bill seeks to ensure that patients have access to safe and effective treatments while also respecting the rights of patent holders.